Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
1. A unit dose of a pharmaceutical composition formulated for treating of an ophthalmic disease or disorder in a subject in need thereof;
wherein the ophthalmic disease is not a cancer;
wherein the composition comprises an amount of a small-molecule means for selectively inhibiting Bcl-2 or Bcl-xL;
wherein the unit dose is formulated with an excipient in a volume suitable for intravitreal administration; and
wherein the formulation of the composition and the amount of the means for selectively inhibiting Bcl-2 or Bcl-xL in the unit dose configure the unit dose to be effective in selectively killing p16 positive senescent cells in the eye that are causing adverse symptoms of the ophthalmic disease or disorder in the subject when administered to the subject intravitreally as a single dose.
2. The unit dose of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is selected from WEHl-539, A-1155463, ABT-737, ABT-199, Obatoclax, BXl-61, BXl-72, 2,3-DCPE, ((R) 4-(4-chlorophenyl)-3-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid (“Compound 21”), (R)-5-(4-chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-ethyl-2-methyl-1H-pyrrole-3-carboxylic acid (“Compound 14”), (R)-5-(4-chlorophenyl)-4-(3-(4-(4-(4-(4-(dimethylamino)-1-(phenylthio)butan-2-ylamino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylic acid (“Compound 15”), BM-957, BM-1074, BM-1197, and salts of any of the aforelisted compounds.
3. The unit dose of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is ABT 263 (Navitoclax) or a salt thereof.
4. The unit dose of claim 1 , wherein the pharmaceutical composition is a sustained-release formulation.
5. The unit dose of claim 1 , wherein the formulation of the composition and the amount of the means for selectively inhibiting Bcl-2 or Bcl-xL in the unit dose configure the unit dose to be effective in delaying disorganization of type IV collagen in the eye.
6. The unit dose of claim 1 ,
wherein the ophthalmic disease is age-related macular degeneration (AMD).
7. The unit dose of claim 1 , packaged in a kit containing a plurality of such doses.
8. A product that comprises a unit dose of a pharmaceutical composition according to claim 1 and a package insert that describes the use and attendant benefits of the composition in treating age-related macular degeneration (AMD).
9. A unit dose of a pharmaceutical composition according to claim 1 , contained in an appliance or device that is configured for administering the pharmaceutical composition it contains intravitreally into an eye of a subject in need thereof.
10. The unit dose of claim 1 , which when administered in or around an eye of a subject in need thereof as a single dose is effective in relieving or delaying progression of one or more of the symptoms of the ophthalmic disease or disorder for at least two weeks.
11. A unit dose of a pharmaceutical composition formulated for treating glaucoma in a subject in need thereof;
wherein the composition comprises an amount of a small-molecule means for selectively inhibiting Bcl-2 or Bcl-xL;
wherein the unit dose is formulated with an excipient in a volume that is suitable for intraocular administration; and
wherein the formulation of the composition and the amount of the means for selectively inhibiting Bcl-2 or Bcl-xL in the unit dose configure the unit dose to be effective in selectively killing p16 positive senescent cells in the eye that are causing adverse symptoms of the glaucoma in the subject when administered to the subject intraocularly as a single dose, thereby decreasing the severity of the one or more symptoms of glaucoma in the eye of the subject for at least two weeks.
12. A product that comprises a unit dose of a pharmaceutical composition according to claim 11 and a package insert that describes the use and attendant benefits of the composition in treating glaucoma.
13. A unit dose of a pharmaceutical composition formulated for treating of an ophthalmic disease or disorder that is not a cancer in an eye of a subject in need thereof;
wherein the composition comprises an effective amount of the compound (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5 fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2 yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (BM-1197) or a salt thereof,
wherein the unit dose is formulated with an excipient in a volume suitable for intravitreal administration; and
wherein the formulation of the composition and the amount of the compound in the unit dose configure the unit dose to be effective in treating the ophthalmic disease or disorder in the subject when administered intravitreally to the subject as a single dose.
14. The unit dose of claim 13 , which when administered in or around an eye of a subject in need thereof is effective in killing senescent cells in the eye that are causing symptoms of the ophthalmic disease or disorder.
15. The unit dose of claim 13 , which when administered in or around an eye of a subject in need thereof is effective in relieving or delaying progression of one or more symptoms of the ophthalmic disease or disorder for at least two weeks.
16. The unit dose of claim 13 ,
wherein the ophthalmic disease is age-related macular degeneration (AMD).
17. The unit dose of claim 13 , packaged in a kit containing a plurality of such doses.
18. A product that comprises a unit dose of a pharmaceutical composition according to claim 13 and a package insert that describes the use and attendant benefits of the composition in treating age-related macular degeneration (AMD).